These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 35567980

  • 1. C2 by-pass: Cross-talk between the complement classical and alternative pathways.
    Laich A, Patel H, Zarantonello A, Sim RB, Inal JM.
    Immunobiology; 2022 May; 227(3):152225. PubMed ID: 35567980
    [Abstract] [Full Text] [Related]

  • 2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ, Ramsey J, Hammer CH, Frank MM.
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I, Sorvillo J, Mecarelli-Halbwachs L, Leibowitch J.
    J Exp Med; 1981 Jul 01; 154(1):1-12. PubMed ID: 7019379
    [Abstract] [Full Text] [Related]

  • 4. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
    Welch TR, Forristal J, Beischel L.
    J Lab Clin Med; 1986 Jun 01; 107(6):529-33. PubMed ID: 3635565
    [Abstract] [Full Text] [Related]

  • 5. Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.
    Yaseen S, Demopulos G, Dudler T, Yabuki M, Wood CL, Cummings WJ, Tjoelker LW, Fujita T, Sacks S, Garred P, Andrew P, Sim RB, Lachmann PJ, Wallis R, Lynch N, Schwaeble WJ.
    FASEB J; 2017 May 01; 31(5):2210-2219. PubMed ID: 28188176
    [Abstract] [Full Text] [Related]

  • 6. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR, Hazevoet HM, Hermans J, van Es LA, Cats A.
    Clin Exp Immunol; 1983 Oct 01; 54(1):248-52. PubMed ID: 6604610
    [Abstract] [Full Text] [Related]

  • 7. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E, Kazatchkine MD, Mecarelli-Halbwachs L.
    Eur J Immunol; 1984 Dec 01; 14(12):1111-4. PubMed ID: 6240408
    [Abstract] [Full Text] [Related]

  • 8. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA, Ruiz-Gómez G, Le GT, Abbenante G, Fairlie DP.
    Biochemistry; 2009 Sep 08; 48(35):8466-72. PubMed ID: 19642650
    [Abstract] [Full Text] [Related]

  • 9. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway.
    Wallis R, Dodds AW, Mitchell DA, Sim RB, Reid KB, Schwaeble WJ.
    J Biol Chem; 2007 Mar 16; 282(11):7844-51. PubMed ID: 17204478
    [Abstract] [Full Text] [Related]

  • 10. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement.
    Rawal N, Rajagopalan R, Salvi VP.
    J Biol Chem; 2008 Mar 21; 283(12):7853-63. PubMed ID: 18204047
    [Abstract] [Full Text] [Related]

  • 11. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV, Shibanova ED, Zinchenko AA.
    Biokhimiia; 1987 Apr 21; 52(4):660-6. PubMed ID: 3647798
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway.
    Hiramatsu M, Tsokos GC.
    Clin Immunol Immunopathol; 1988 Jan 21; 46(1):91-9. PubMed ID: 2826058
    [Abstract] [Full Text] [Related]

  • 13. Formation of high affinity C5 convertase of the classical pathway of complement.
    Rawal N, Pangburn MK.
    J Biol Chem; 2003 Oct 03; 278(40):38476-83. PubMed ID: 12878586
    [Abstract] [Full Text] [Related]

  • 14. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
    Kinoshita T, Dodds AW, Law SK, Inoue K.
    Biochem J; 1989 Aug 01; 261(3):743-8. PubMed ID: 2803239
    [Abstract] [Full Text] [Related]

  • 15. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB, Forristal J, Beischel L, West CD.
    J Clin Invest; 1985 Jun 01; 75(6):1786-95. PubMed ID: 3159752
    [Abstract] [Full Text] [Related]

  • 16. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
    Kerr MA, Parkes C.
    Biochem J; 1984 Apr 15; 219(2):391-9. PubMed ID: 6611150
    [Abstract] [Full Text] [Related]

  • 17. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK.
    J Immunol; 1986 Mar 15; 136(6):2216-21. PubMed ID: 2419425
    [Abstract] [Full Text] [Related]

  • 18. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
    Takata Y, Kinoshita T, Kozono H, Takeda J, Tanaka E, Hong K, Inoue K.
    J Exp Med; 1987 Jun 01; 165(6):1494-507. PubMed ID: 3495629
    [Abstract] [Full Text] [Related]

  • 19. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway).
    Thielens NM, Colomb MG.
    Eur J Immunol; 1986 Jun 01; 16(6):617-22. PubMed ID: 3487454
    [Abstract] [Full Text] [Related]

  • 20. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
    Garred P, Mollnes TE, Thorsteinsson L, Erlendsson K, Steinsson K.
    Scand J Immunol; 1990 Jan 01; 31(1):59-64. PubMed ID: 2300790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.